CASP3 and Familial prostate cancer: The Z-VAD-FMK pan-caspase inhibitor interfered with the P5091-induced citotoxicity in the castration-resistant 22Rv1 prostate cancer cells (Figure 2B); moreover, we observed the activation of the caspase 3 upon P5091 treatment in these cells (Figure 2C).